KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Gsk (GSK) over the last 15 years, with Q4 2025 value amounting to $2.7 million.

  • Gsk's Long-Term Debt Repayments fell 9987.17% to $2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.9 billion, marking a year-over-year decrease of 2559.94%. This contributed to the annual value of -$1.8 billion for FY2025, which is 1056.91% up from last year.
  • According to the latest figures from Q4 2025, Gsk's Long-Term Debt Repayments is $2.7 million, which was down 9987.17% from $9.4 million recorded in Q3 2025.
  • Gsk's 5-year Long-Term Debt Repayments high stood at $2.8 billion for Q4 2023, and its period low was -$175.0 million during Q1 2023.
  • Its 4-year average for Long-Term Debt Repayments is $1.1 billion, with a median of $939.5 million in 2022.
  • In the last 5 years, Gsk's Long-Term Debt Repayments soared by 5002.84% in 2023 and then plummeted by 9987.17% in 2025.
  • Gsk's Long-Term Debt Repayments (Quarter) stood at $1.9 billion in 2022, then soared by 50.03% to $2.8 billion in 2023, then fell by 26.1% to $2.1 billion in 2024, then crashed by 99.87% to $2.7 million in 2025.
  • Its Long-Term Debt Repayments was $2.7 million in Q4 2025, compared to $9.4 million in Q3 2025 and $2.1 billion in Q4 2024.